Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis in Clinical Trials: A Systematic Review and Meta-analysis
This study demonstrates that attainment of ASDAS inactive disease in axSpA clinical trials is consistently low, reflecting the stringency of this remission threshold within trial designs. These findings underscore the importance of interpreting ASDAS-ID alongside ASDAS-LDA, which may represent a more attainable and clinically meaningful disease state when remission is not achieved.
Authors
- Sohi Mistry (ORCID: https://orcid.org/0000-0003-0241-1914)
- Marina Magrey (ORCID: https://orcid.org/0000-0002-6520-5619)
- Haseeb Chaudhary (ORCID: https://orcid.org/0000-0001-6722-0372)
- S. Abi Doumeth
- Emily Petrinec
- Jenny Gong (ORCID: https://orcid.org/0000-0002-6595-8610)
- Ömer Nurı Pamuk (ORCID: https://orcid.org/0000-0001-5377-5879)
- Alexandre Matar
Institutions
- Summa Health System (US)
- University Hospitals of Cleveland (US)
- MetroHealth Medical Center (US)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-03-15
- DOI
- https://doi.org/10.3899/jrheum.2025-0553
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00